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Abstract
Pyoderma gangrenosum (PG) is an uncommon, ulcerative skin disease that is often associated with systemic
diseases. Herein, we report a development of PG in a surgical site after cholecystectomy that was difficult to
discriminate from surgical site infection. The patient was a 74-year-old man who had previously been diagnosed
with myelodysplastic syndrome (MDS). Laparoscopic cholecystectomy was planned under diagnosis of
cholecystolithiasis, but we converted to open cholecystectomy. The surgical wound was partially erythematous
4 days after surgery. In spite of opening the wound, cleansing it with sterile saline, and administration of antibiotics,
inflammation spread with erosion. The clinical manifestations and histopathologic features of biopsy specimen
indicated that diagnosis of PG associated with MDS was most likely. Administration of glucocorticoids made a rapid
response of skin inflammation. The differential diagnosis of postoperative wound healing complications that were
unresponsive to conventional wound local care and antibiotic therapy should include PG, especially in patients with
systemic diseases such as MDS.
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Background
Pyoderma gangrenosum (PG) is an uncommon, ulcerative
skin disease, and characterized by a rapidly enlarging
necrotic ulceration with an undermined border and a sur-
rounding of erythema [1–5]. It is often associated with
systemic illness, such as inflammatory bowel disease
(IBD), rheumatoid arthritis (RA), and myelodysplastic
syndrome (MDS) [6, 7]. Recently, several manuscripts re-
ported that PG could also occur after surgery and local
trauma [8–10]. Herein, we report a development of PG in
a surgical site after cholecystectomy that was difficult to
discriminate from surgical site infection.
Case presentation
The patient was a 74-year-old man who had previ-
ously been diagnosed with MDS. He was diagnosed
with calculous cholecystolithiasis at our hospital.
Laparoscopic cholecystectomy was planned, but we
converted to open cholecystectomy with a right sub-
costal oblique incision because it was difficult to
remove the impacted calculus in the cystic duct. The
surgical wound was partially erythematous 4 days
after surgery (Fig. 1a), so we opened the wound and
cleanse with sterile saline and performed moist envir-
onment dressing because of surgical site infection
suspected. Inflammation, however, spread to the sur-
rounding skin with erosion (Fig. 1b). The condition of
wound rapidly deteriorated, so we introduced intra-
wound continuous negative pressure and irrigation
treatment (IW-CONPIT) 10 days after surgery
(Fig. 1c). In spite of IW-CONPIT, inflammation
continued to further spread widely with a purulent
coating (Fig. 1d). In addition, skin edema spread from
the lower back to the lower extremities. Antibiotic ad-
ministration and irrigation were not effective, either.
Bacteriological examination revealed that Enterococcus
faecalis and Pseudomonas aeruginosa were detected in
the wound, although those counts were low. We
decided to perform biopsy of the skin surrounding the
wound to analyze pathological condition. Histopatho-
logic feature showed that severe inflammatory cell, pre-
dominantly of neutrophils, infiltrated in the dermis, and
no bacterial components were observed (Fig. 2a, b).
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These clinical and histopathologic findings of the
surgical site indicated that diagnosis of PG associ-
ated with MDS was most likely. After the addition
of a systemic administration of 30 mg/day prednisol-
one to local care of the surgical site with moist
dressing, fever had been rapidly alleviated, spread of
rash had diminished, edema in the lower body had
improved, and the purulent coating had disappeared
on the eroded skin surface surrounding the open
wound (Fig. 3a). Elevated CRP (18.1 mg/dL) and
WBC counts (40.5 × 103 μL) before administration of
prednisolone had been improved remarkably, and
these data became within normal ranges after
2 weeks, so the dose of prednisolone was tapered to
25 mg/day. The dose had been reduced 5 mg/day
per 1–2 months to follow up the skin and general
condition, including laboratory data. Erosion had
healed and epithelialization occurred. The surface of
the wound was covered with satisfactory granulation
tissue, and normal wound healing was achieved after
administration of 5 mg/day prednisolone for 1 year
(Fig. 3b).
Discussion
PG is an uncommon, chronic, recurrent, and painful
cutaneous ulcerative disease with a distinctive
Fig. 1 Erythema occurred in the surgical site 4 days after surgery (a). The skin inflammation change spread with erosion despite that moist
environment dressing was introduced (b). The intra-wound continuous negative pressure and irrigation treatment (IW-CONPIT) was also introduced
from 10 days after surgery (c). Inflammation continued to further spread with a purulent coating even after IW-CONPIT (d)
Fig. 2 Histological findings of the skin biopsy revealed that severe inflammatory cell, predominantly of neutrophils, infiltrated in the dermis, and
no bacterial components were observed. Hematoxylin-eosin stain ×40 (a), ×100 (b)
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morphologic presentation and uncertain etiology. The
lower extremities are most common sites of involvement,
though rare subtype of cases appears stoma site on ulcera-
tive colitis increased recently [11]. More than half of
patients with PG suffer from an associated systemic dis-
ease such as IBD, RA, and MDS [6, 7]. In this case, there
was a history of MDS: it was to help diagnosis of PG.
Development of PG in a surgical and trauma site is
rare and occurs mainly within 2 weeks after surgery [12].
The initial symptoms are surgical site erythema and
extreme pain out of proportion to the physical examin-
ation [13–17]. PG is often initially diagnosed as a surgi-
cal site infection, though treatment with antibiotics and
wound debridement fails to arrest rapid ulcer enlarge-
ment. Our case was also regarded as infection to treat
with antibiotics, open drainage, and continuous wound
lavage, but the condition had been getting worse. We
performed excisional biopsy to clarify pathogenesis of
the cutaneous lesion. Histopathologic findings revealed
non-specific and neutrophil-dominant inflammation, but
bacterial infection could be denied. The clinical and
histopathological manifestations indicated that diagnosis
of PG associated with MDS was most likely. Histological
examination should be performed to exclude other dis-
orders such as vasculitis, pyoderma, and vasculopathies,
when the administration of antibiotic, debridement, and
irrigation for inflammatory surgical site is ineffective and
makes clinical exacerbation. A diagnosis of PG could be
made when other diagnostic possibilities had been ex-
cluded, because no accepted diagnostic criteria existed.
Su WP et al. proposed diagnostic criteria, including
clinical and histopathologic findings and treatment re-
sponse [18]. Post-surgical PG occurred after breast
(25 %), cardiothoracic (14 %), abdominal (14 %), and
obstetric (13 %) surgeries [19], could deny infection and
other possibilities, suspected PG, and performed experi-
mental administration of steroid, following respond
dramatically. PG has a good prognosis if appropriate
therapy is immediately selected for it, but unless it is
done, its prognosis becomes worse rapidly; it is likely to
progress to death with consequent sepsis [20].
Definitive guidelines for treatment of PG are lacking.
Patients with PG are treated with local and/or systemic
therapies. First, to make an optimal environment for
wound healing, a moist wound environment after cleans-
ing with sterile saline is required [21]. Local administra-
tion of corticosteroids could be used in patients with mild
PG, though the efficacy of these drugs is limited to a few
retrospective studies and case reports [22, 23]. In contrast,
systemic therapy is necessary in patients with more severe
PG. Glucocorticoids are mostly selected for systemic
drugs [22, 24]. Zuo et al. reported that most patients were
treated with oral prednisolone (0.5–1.5 mg/kg/day) or
intravenous methylprednisolone (0.5–1 mg/kg/day) com-
bined with/without immunosuppressants such as systemic
or topical tacrolimus [19]. We administered oral
prednisolone 30 mg/day (0.5 mg/kg/day) as initial
treatment and by means of diagnostic administration.
If this administration is not effective, the dose of
oral prednisolone could increase or administrations
of intravenous methylprednisolone and tacrolimus
ointment could be selected. Topical tacrolimus is
one of the effective local treatments for PG [25].
Cyclosporine exhibited equivalent effect compared with
steroids as a systemic treatment in a randomized trial
[26]. A wide variety of other systemic immunomodulatory
drugs, including anti-tumor necrosis factor alpha agents
could be also utilized as alternative or adjunctive
treatments in patients with PG that fails to respond to
glucocorticoids [2, 27].
Conclusions
The differential diagnosis of postoperative wound
healing complications that were unresponsive to con-
ventional wound debridement or antibiotic therapy
should include PG, especially in patients with sys-
temic diseases such as MDS. Glucocorticoids make a
rapid response in patients with postoperative PG.
Fig. 3 After the systemic administration of glucocorticoid, the purulent coating had disappeared on the eroded skin surface in the surroundings
of the open wound. In addition, erosion had healed and there was promotion of epithelialization (a). One year after surgery, normal wound
healing was achieved (b)
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Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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